Isaac E. Marx

Sulfonamides as Selective Na_V1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity

Russell F. Graceffa, Alessandro A. Boezio, Jessica Able et al. · Journal of Medicinal Chemistry · 2017 · 66 citations · Full text

Inhibitors of β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1): Identification of (<i>S</i>)-7-(2-Fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5′<i>H</i>-spiro[chromeno[2,3-<i>b</i>]pyridine-5,4′-oxazol]-2′-amine (AMG-8718)

Thomas A. Dineen, Kui Chen, Alan C. Cheng et al. · Journal of Medicinal Chemistry · 2014 · 61 citations · Full text

Aminooxazoline Xanthene Scaffold, Pharmacotherapy, Potential Herg Liabilities +20

Sulfonamides as Selective Na_V1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities

Matthew M. Weiss, Thomas A. Dineen, Isaac E. Marx et al. · Journal of Medicinal Chemistry · 2017 · 49 citations · Full text

Lead Optimization and Modulation of hERG Activity in a Series of Aminooxazoline Xanthene β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors

O. I. Epstein, Marian C. Bryan, Alan C. Cheng et al. · Journal of Medicinal Chemistry · 2014 · 40 citations · Full text

Pharmacotherapy, Enzyme 1, Chemical Biology +19

Sulfonamides as Selective Na_V1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target Engagement

Isaac E. Marx, Thomas A. Dineen, Jessica Able et al. · ACS Medicinal Chemistry Letters · 2016 · 37 citations · Full text